一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可[2021]757 号核准，并经深圳证券交易 所同意，本公司由主承销商中信证券股份有限公司通过深圳证券交易所系统于 2021 年 3 月 29 日采用全部向二级市场投资者定价配售方式，向社会公众公开发 行了普通股（A 股）股票 1,459.00 万股，发行价为每股人民币 44.77 元。截至 2021 年 4 月 2 日，本公司共募集资金 65,319.43 万元，扣除发行费用后募集资金净额 为 59,610.98 万元。 关于 2023 年半年度募集资金存放与使用情况的 专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 依照《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》和《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》以及相关格式指引的规定，江苏华绿生物科技股份有限公 司（以下简称"公司"）董事会编制了 2023 年半年度募集资金年度存放与使用 情况的专项报告。 证券代码：300970 ...

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于 江苏华绿生物科技股份有限公司 2023年限制性股票激励计划首次授予相关事宜 的 法律意见书 地址：上海市浦东新区银城中路501号上海中心大厦9/11/12层 电话：021-20511000 传真：021-20511999 邮编：200120 | 《公司法》 | 指 | 《中华人民共和国公司法》 | | --- | --- | --- | | 《证券法》 | 指 | 《中华人民共和国证券法》 | | 《管理办法》 | 指 | 《上市公司股权激励管理办法》 | | 《公司章程》 | 指 | 《江苏华绿生物科技股份有限公司章程》 | | 《上市规则》 | 指 | 《深圳证券交易所创业板股票上市规则》 | | 《自律监管指南》 | 指 | 《深圳证券交易所创业板上市公司自律监管指南第1 | | | | 号——业务办理》 | | 中国证监会 | 指 | 中国证券监督管理委员会 | | 深交所 | 指 | 深圳证券交易所 | | 元 | 指 | 如无特别说明，指人民币元 | 注：本法律意见书若出现总数合计与各分项数值之和尾数不符的，系四舍五入原因造成。 上 ...

证券代码：300970 证券简称：华绿生物 公告编号：2023-064 激励对象名单的核实意见 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 江苏华绿生物科技股份有限公司（以下简称"公司"）第五届监事会第三次 会议于 2023 年 8 月 18 日召开，会议审议通过了《关于向 2023 年限制性股票激 励计划激励对象首次授予限制性股票的议案》。 公司监事会依照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以 下简称"《管理办法》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上 市规则》"）、《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办 理》（以下简称"《业务办理》"）和《江苏华绿生物科技股份有限公司章程》（以 下简称"《公司章程》"）等有关规定，对公司 2023 年限制性股票激励计划首次授 予日的激励对象名单进行审核，发表核实意见如下： 一、首次获授限制性股票的激励对象符合《公司法》《证券法》《公司章程》 等规定的任职资格，符合《上市规则》 ...

证券代码：300970 证券简称：华绿生物 公告编号：2023-062 江苏华绿生物科技股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记 载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 江苏华绿生物科技股份有限公司（以下简称"公司"）第五届监事会第三次 会议于 2023 年 8 月 18 日以现场和通讯相结合的方式在公司会议室召开，会议通 知于 2023 年 8 月 10 日以通讯方式向全体监事送达。会议应出席监事 3 人，实际 出席监事 3 人。公司董事会秘书列席了本次会议，会议由监事会主席李贺文先生 主持。本次监事会的召开符合《中华人民共和国公司法》等有关法律、行政法规 、部门规章、规范性文件及《公司章程》的规定。 二、监事会会议审议情况 经与会监事认真审议，形成如下决议： （一）审议通过了《关于<公司 2023 年半年度报告>及其摘要的议案》 经审议，监事会认为：董事会编制和审核《公司 2023 年半年度报告》及其 摘要的程序符合法律、行政法规和中国证监会的相关规定，报告内容真实、准确 、完整地反映了公司的实际情况，不存在任何虚假 ...

投资者关系活动记录表 编号：2023—001 证券代码：300970 证券简称：华绿生物 江苏华绿生物科技股份有限公司 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 类别 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他（请文字说明其他活动内容） | | 参与单位名称及 | 线上参与公司2022年度业绩网上说明会的投资者 | | 人员姓名 | | | 时间 | 年 5月 日(星期四)下午 2023 18 15:00-17:00 | | 地点 | 互动易云访谈 | | 上市公司接待人 | 董事长、总经理余养朝先生，董事、董事会秘书、财务负责人钱韬先生， | | 员姓名 | 独立董事谢南女士，保荐代表人韩昆仑先生。 | | | 华绿生物于 2023 年5月18 日（星期四）下午15:00 至17:00 在互动易举 行 年度业绩网上说明会，本次网上说明会采用网络远程的方式 2022 举行，网上说明会问答环节主要内容如下： | | | 1、贵公司2022年度业绩大幅增长的原因？ | | 投资者关系活动 | | | 主要内容介 ...

证券代码：300970 证券简称：华绿生物 公告编号：2023-026 江苏华绿生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 出席本次说明会的人员有：公司董事长、总经理余养朝先生，董事、董事会 秘书、财务总监钱韬先生，独立董事谢南女士，保荐代表人韩昆仑先生。（如有 特殊情况，参会人员将有可能进行调整） 为做好中小投资者保护工作，增进投资者对公司的了解和认同，提升交流的 针对性，现就公司 2022 年度网上业绩说明会提前向投资者公开征集相关问题。 投资者可提前登录深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn）"云 访谈"栏目进入公司本次说明会页面进行提问。公司将在 2022 年度网上业绩说 明会上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与。 特此公告。 江苏华绿生物科技股份有限公司 董事会 2023 年 4 月 28 日 江苏华绿生物科技股份有限公司（以下简称"公司"）《2022 年年度报告》 全文及摘要已于 2023 年 4 月 24 日披露 ...

Financial Performance - The company's operating revenue for 2022 was ¥751,593,906.93, representing a 30.01% increase compared to ¥578,088,209.15 in 2021[18]. - The net profit attributable to shareholders for 2022 was ¥78,252,313.54, a significant increase of 404.70% from ¥15,504,571.94 in 2021[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥63,889,146.99, up 1,531.44% from ¥3,916,130.92 in 2021[18]. - The net cash flow from operating activities reached ¥179,842,048.50, an increase of 116.46% compared to ¥83,083,400.59 in 2021[18]. - The total assets at the end of 2022 were ¥1,980,363,134.91, reflecting a 5.53% increase from ¥1,876,521,079.39 at the end of 2021[18]. - The company's basic earnings per share for 2022 was ¥0.67, a 378.57% increase from ¥0.14 in 2021[18]. - The total revenue from the main business for 2022 was CNY 751,593,906.93, representing a year-on-year increase of 16.32%[51]. - The sales volume of edible mushrooms reached 133,692.45 tons, an increase of 4.58% compared to 2021[51]. - The production volume of edible mushrooms was 133,450.48 tons, reflecting a growth of 3.59% year-on-year[51]. - The gross profit margin for the edible mushroom segment was 16.32%, reflecting a year-on-year increase of 9.66%[50]. Dividend and Shareholder Returns - The company reported a cash dividend of 2 RMB per 10 shares (including tax) based on a total share capital of 11.67 million shares as of December 31, 2022[4]. - The cash dividend represents 33.24% of the distributable profit of 70,218,170.36 CNY for the reporting period[141]. - The company plans to distribute a cash dividend of 2.0 CNY per 10 shares, totaling 23,340,000 CNY (including tax) based on a total share capital of 11,670,000 shares[141]. - The cash dividend distribution complies with the company's articles of association and relevant regulations[140]. - The company has established a complete decision-making process for the cash dividend policy, ensuring transparency and protection of minority shareholders' rights[140]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements and performance forecasts in the annual report[4]. - The company has detailed potential risk factors that may affect future development in the management discussion and analysis section[4]. - The company faces risks from intensified market competition, which may lead to price declines and fluctuations in gross margins[91]. - The company is facing risks from raw material price fluctuations, which significantly impact production costs and gross margins[92]. - The company is monitoring tax policy changes that could impact its exemption from VAT and corporate income tax, which currently benefits its net profit[95]. Research and Development - Research and development expenses totaled over ¥14 million, with 21 new patents granted, enhancing the company's technological strength and core competitiveness[46]. - The R&D team is composed of experienced professionals from agriculture, food, and biology, supporting the company's innovation capabilities[36]. - The company aims to complete 2-3 suitable culture media for Cordyceps flower cultivation, which is expected to enhance production efficiency and quality[58]. - The company is developing a complete set of breeding systems for edible mushrooms, focusing on high-yield and quality strains suitable for industrial cultivation[59]. - R&D investment in 2022 amounted to ¥14,041,002.29, representing a significant increase from ¥8,624,943.56 in 2021, marking a growth of 62.5%[59]. Corporate Governance - The company has established a complete governance structure, including a board of directors, supervisory board, and shareholder meetings, all operating independently from the controlling shareholder[108]. - The company has a strategic committee that reviews major investment and financing plans, ensuring due diligence in decision-making[101]. - The company has a dedicated audit committee that oversees financial reporting and internal controls, ensuring compliance and accuracy[101]. - The company has implemented a robust investor relations management system, enhancing transparency and communication with investors[102]. - The company has established independent personnel, financial, and operational systems, ensuring no overlap with the controlling shareholder's enterprises[105]. Market Position and Strategy - The company is positioned in the agricultural sector, specifically in the cultivation of edible fungi, which is experiencing a shift towards factory-based production models[28]. - The factory-based cultivation model is gaining market share due to its advantages in quality and efficiency, while traditional farming methods are declining[29]. - The company is recognized as a national key leading enterprise in agricultural industrialization and a high-tech enterprise by the Ministry of Agriculture and Rural Affairs[30]. - The company aims to consolidate its leading position in the edible mushroom market while gradually implementing a nationwide layout strategy[89]. - The company plans to strengthen its brand marketing and channel construction, focusing on expanding sales in supermarkets and restaurants to increase market share[91]. Employee and Talent Management - The total number of employees at the end of the reporting period is 2,197, with 1,731 in production, 282 in technical roles, and 28 in sales[134]. - The company has established a talent training system focusing on skill-based and comprehensive management pathways, including various training programs for new employees and safety education[137]. - The company emphasizes a fair and sustainable compensation system, which includes basic salary, skill wages, performance bonuses, and various benefits[136]. - The company has 300 retired employees for whom it bears costs, indicating a commitment to employee welfare[134]. - The company will invest in high-level talent recruitment and training to build a professional team, which is a key focus for 2023[90]. Social Responsibility - The company actively fulfilled social responsibilities, focusing on creating value for shareholders while ensuring compliance with labor laws and protecting employee rights[156]. - The company established a demonstration workshop for employment poverty alleviation in December 2018, specifically designed to absorb rural impoverished laborers, contributing to local employment[161]. - The workshop operates with low technical requirements and minimal labor intensity, making it accessible for local villagers[161]. - The company aims to continue fulfilling its social responsibilities by providing more job opportunities for disadvantaged groups and supporting rural revitalization efforts[161]. Financial Management and Fund Utilization - The company has established dedicated accounts for the management of raised funds, ensuring proper oversight and usage[77]. - The company is focused on enhancing the efficiency of raised fund usage to protect investor interests and comply with regulatory requirements[77]. - The company plans to strengthen budget management to improve fund utilization efficiency and reduce expenses[180]. - The company will enhance product diversity and improve market competitiveness by expanding research, production, and sales of other edible mushroom products[180]. - The company has promised to adhere to the profit distribution policy as outlined in its articles of association following its IPO[180].

Financial Performance - The company's revenue for Q1 2023 reached ¥332,570,440.03, representing a 94.81% increase compared to ¥170,717,067.49 in the same period last year[3]. - Net profit attributable to shareholders was ¥130,078,277.07, a significant increase of 386.55% from ¥26,734,954.17 year-on-year[3]. - Basic earnings per share rose to ¥1.11, reflecting a 382.61% increase from ¥0.23 in the same period last year[3]. - The net profit for Q1 2023 was CNY 130,562,704.27, a significant increase from CNY 26,747,582.62 in Q1 2022, representing a growth of approximately 387.5%[18]. - Operating profit for Q1 2023 reached CNY 130,874,430.89, compared to CNY 26,795,582.62 in the same period last year, indicating a substantial increase[18]. - The total comprehensive income for Q1 2023 was CNY 130,562,704.27, compared to CNY 26,747,582.62 in the same quarter last year, showing a growth of approximately 387.5%[19]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥141,897,609.33, up 164.11% from ¥53,725,956.55 in the previous year[3]. - Cash flow from operating activities generated CNY 141,897,609.33 in Q1 2023, compared to CNY 53,725,956.55 in Q1 2022, marking an increase of approximately 163.5%[22]. - Cash and cash equivalents at the end of Q1 2023 were RMB 625,681,712.53, an increase of 45.0% from RMB 431,650,815.29 at the beginning of the year[14]. - Cash and cash equivalents at the end of Q1 2023 amounted to CNY 625,681,712.53, an increase from CNY 605,921,777.86 at the end of Q1 2022[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,139,389,690.40, an increase of 8.03% from ¥1,980,363,134.91 at the end of the previous year[3]. - The total assets as of March 31, 2023, were RMB 2,139,389,690.40, compared to RMB 1,980,363,134.91 at the beginning of the year, indicating a growth of 8.0%[16]. - The total liabilities increased to RMB 473,389,339.45 from RMB 457,825,488.23, representing a rise of 3.7%[16]. Research and Development - The company reported a 90.20% increase in R&D expenses, totaling ¥3,201,710.64, due to increased investment in research and development[7]. - Research and development expenses rose to CNY 3,201,710.64 in Q1 2023, up from CNY 1,683,353.92 in Q1 2022, reflecting a year-over-year increase of about 90.3%[18]. Operational Costs - The company experienced a 31.10% rise in main business costs, amounting to ¥188,370,721.20, primarily due to the production commencement of a new facility[7]. - The total operating costs for Q1 2023 amounted to RMB 203,831,933.89, up from RMB 148,586,196.63, reflecting a year-over-year increase of 37.2%[17]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,347[10]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to sustain growth[3]. - There are no significant market expansion or acquisition strategies detailed in the report, indicating a focus on internal growth and financial stability[13]. - The company has no new product or technology developments mentioned in the report, focusing instead on financial performance and asset management[13].

证券代表：300970 证券简称：华绿生物 江苏华绿生物科技股份有限公司 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | |---------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------| | 投资者关系活动类别 | 特定对象调研 \n 业绩说明会 \n动 \n 现场参观 | 分析师会议 \n 新闻发布会 \n其他（请用文字说明其他活动内容） | 媒体采访 \n 路演活 | | 参与单位名称及人员姓名 | 参与公司 2020 | 年度业绩网上说明会的投资者 | | | 时间 2021 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥233,070,519.45, representing a 66.74% increase compared to the same period last year[4] - Net profit attributable to shareholders was ¥66,601,174.03, a significant increase of 1,696.20% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥63,509,904.69, up 978.64% from the previous year[4] - Total operating revenue for the third quarter reached CNY 527.72 million, a significant increase of 38.4% compared to CNY 381.34 million in the same period last year[21] - Net profit for the quarter was CNY 66.39 million, a turnaround from a net loss of CNY 4.03 million in the previous year[24] - Earnings per share (EPS) for the quarter was CNY 0.5735, compared to a loss per share of CNY 0.0352 in the same quarter last year[24] Cash Flow and Liquidity - The operating cash flow net amount for the year-to-date period was ¥131,898,539.63, reflecting a remarkable increase of 5,717.78%[10] - The net cash flow from operating activities for the quarter was ¥131,898,539.63, driven by increased product sales[10] - The net cash flow from operating activities for the current period is ¥131,898,539.63, a significant increase from ¥2,267,161.54 in the previous period, reflecting strong operational performance[25] - The total cash and cash equivalents at the end of the period stand at ¥320,929,060.48, down from ¥739,584,919.14 in the previous period, indicating a decrease in liquidity[27] - The cash flow from operating activities totaled ¥571,219,409.40, compared to ¥387,418,472.37 in the previous period, reflecting improved sales performance[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,981,530,026.60, a 5.60% increase from the end of the previous year[5] - Total current assets decreased from ¥919,810,557.90 to ¥799,938,210.68, a decline of about 13.0%[18] - Total liabilities rose to CNY 473.44 million, compared to CNY 438.92 million in the previous year, marking an increase of 7.4%[20] - The company's equity attributable to shareholders reached CNY 1.50 billion, an increase from CNY 1.43 billion, representing a growth of 4.5%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,633[12] - The largest shareholder, Yu Yangchao, holds 30.84% of shares, totaling 35,987,628 shares[12] - The top ten shareholders include Jiangsu Gaotou Development Venture Capital Co., holding 7.40% of shares[12] Research and Development - Research and development expenses increased by 63.42% to ¥10,425,054.33, indicating a focus on innovation[10] - Research and development expenses for the quarter were CNY 10.43 million, up 63.9% from CNY 6.38 million in the previous year, indicating a strong focus on innovation[21] Inventory and Operational Costs - The company reported a significant increase in inventory by 31.04% to ¥141,420,684.26, attributed to business expansion[10] - Operating costs amounted to CNY 473.59 million, up 19.6% from CNY 396.23 million year-on-year[21] - Inventory increased from ¥107,921,860.27 to ¥141,420,684.26, an increase of approximately 30.9%[18] Investment Activities - Total cash inflow from investment activities reached ¥1,507,677,172.56, compared to ¥39,644,265.37 in the previous period, indicating a substantial increase in investment activity[27] - The company reported an investment income of CNY 2.33 million, compared to CNY 0.62 million in the same period last year, reflecting a positive trend in investment performance[21] - The company received cash from the absorption of investments amounting to ¥4,100,000.00, up from ¥500,000.00 in the previous period, reflecting increased investor confidence[27] Other Information - The company has not reported any new product developments or market expansions in the current quarter[13] - There are no indications of mergers or acquisitions in the recent financial disclosures[13] - The company has a total of 48,360,504 restricted shares, all of which are subject to lock-up until April 11, 2024[16]